Briefing
ctDNA-guided de-escalation of adjuvant chemotherapy with dalpiciclib in HR-positive HER2-negative breast cancer
Phase 2 trial titled as ctDNA-guided de-escalation. Registry primary outcomes are the ctDNA clearance rate after neoadjuvant therapy and 3-year event-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting